Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Director · President & CEO | August 18, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEKTAR THERAPEUTICS
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,627 |
Reported balance
After 2026-08-18 transaction · row 1
1 source rowRow 1 · 2026-08-18 · Sale · Disposed 418 · Balance 54,627 F1: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2: This transaction was executed in multiple trades at prices ranging from $71.78 to $72.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
| Common StockSEC Table I · non-derivative | Indirectby spouse | 28 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 28 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.
F2: This transaction was executed in multiple trades at prices ranging from $71.78 to $72.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2021 Filed Dec 21, 2021 01:25 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 223,750 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001209191-21-070692 · doc4.xml · derivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,750 Underlying: Common Stock · 223,750 shares Expires 2029-12-15 F2 · derivative.exercise_date: This stock option vests over four years from the date of grant in equal monthly installments based on continued service. Read SEC document |
| December 16, 2021 Filed Dec 21, 2021 01:25 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 126,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070692 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601,500 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. These RSUs vest over three years from the date of grant in substantially equal quarterly installments based on continued service. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 23:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 42,773 | $13.16 | $562,892.68 |
DisclosureSEC source: 0001209191-21-065222 · doc4.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,450 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $12.84 to $13.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 94,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-065222 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 518,223 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 12, 2019 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. F2 · date: The Organization and Compensation Committee of the Board of Directors of the Issuer determined that the performance-based vesting requirement for these RSUs was satisfied on September 15, 2021. Pursuant to the terms of the 2017 Plan, these RSUs vested on the next quarterly vesting date (November 15, 2021) following the date that the performance-based vesting requirement was satisfied. Read SEC document |
| October 12, 2021 Filed Oct 15, 2021 01:06 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 167,650 | $0.00 Strike: $21.79 | $0.00 |
DisclosureSEC source: 0001209191-21-060510 · doc4.xml · derivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,650 Underlying: Common Stock · 167,650 shares Expires 2027-12-11 F1 · security: These stock options were granted on December 12, 2019 under the Company's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. F2 · date: The Organization and Compensation Committee of the Board of Directors of the Company determined that the performance-based vesting requirement for these stock options was satisfied on September 15, 2021. Pursuant to the terms of the 2017 Plan, these stock options vested on the next monthly vesting date (October 12, 2021) following the date that the performance-based vesting requirement was satisfied. F3 · derivative.exercise_date: These stock options vest on a monthly pro-rata basis over a period of four years from the grant date (December 12, 2019). Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 23:01 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 11,515 | $13.83 | $159,252.45 |
DisclosureSEC source: 0001209191-21-052391 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,123 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.69 to $14.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| May 17, 2021 Filed May 19, 2021 23:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 11,560 | $18.30 | $211,548.00 |
DisclosureSEC source: 0001209191-21-034187 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,638 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.95 to $18.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 11,495 | $22.37 | $257,143.15 |
DisclosureSEC source: 0001209191-21-012121 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 447,198 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.04 to $22.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 01:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 150,000 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001209191-21-007944 · doc4.xml · derivative · entry 15 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2021-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 01:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 58,137 | $20.58 | $1,196,459.46 |
DisclosureSEC source: 0001209191-21-007944 · doc4.xml · nonDerivative · entry 10 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 458,693 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. F7 · price: This transaction was executed in multiple trades at prices ranging from $20.51 to $20.66. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 01:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 91,863 | $20.10 | $1,846,446.30 |
DisclosureSEC source: 0001209191-21-007944 · doc4.xml · nonDerivative · entry 9 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 516,830 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. F6 · price: This transaction was executed in multiple trades at prices ranging from $19.50 to $20.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 01:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 150,000 | $8.80 | $1,320,000.00 |
DisclosureSEC source: 0001209191-21-007944 · doc4.xml · nonDerivative · entry 8 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 01:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 75,000 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001209191-21-007944 · doc4.xml · derivative · entry 14 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 75,000 shares Expires 2021-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 01:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 75,000 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001209191-21-007944 · doc4.xml · derivative · entry 13 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2021-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 01:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 150,000 | $19.72 | $2,958,000.00 |
DisclosureSEC source: 0001209191-21-007944 · doc4.xml · nonDerivative · entry 7 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 458,693 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. F5 · price: This transaction was executed in multiple trades at prices ranging from $19.26 to $19.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 01:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 75,000 | $8.80 | $660,000.00 |
DisclosureSEC source: 0001209191-21-007944 · doc4.xml · nonDerivative · entry 6 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 01:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 75,000 | $8.80 | $660,000.00 |
DisclosureSEC source: 0001209191-21-007944 · doc4.xml · nonDerivative · entry 5 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 533,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. Read SEC document |
| February 02, 2021 Filed Feb 5, 2021 01:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 150,000 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001209191-21-007944 · doc4.xml · derivative · entry 12 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 150,000 shares Expires 2021-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. Read SEC document |
| February 02, 2021 Filed Feb 5, 2021 01:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 600 | $21.59 | $12,954.00 |
DisclosureSEC source: 0001209191-21-007944 · doc4.xml · nonDerivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 458,693 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $21.43 to $21.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 02, 2021 Filed Feb 5, 2021 01:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 9,900 | $20.84 | $206,316.00 |
DisclosureSEC source: 0001209191-21-007944 · doc4.xml · nonDerivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,293 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $20.42 to $21.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 02, 2021 Filed Feb 5, 2021 01:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 139,500 | $19.69 | $2,746,755.00 |
DisclosureSEC source: 0001209191-21-007944 · doc4.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,193 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.41 to $20.41. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 02, 2021 Filed Feb 5, 2021 01:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 150,000 | $8.80 | $1,320,000.00 |
DisclosureSEC source: 0001209191-21-007944 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:50 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 190,650 | $0.00 Strike: $18.75 | $0.00 |
DisclosureSEC source: 0001209191-20-064915 · doc4.xml · derivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,650 Underlying: Common Stock · 190,650 shares Expires 2028-12-17 F2 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:50 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 106,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-064915 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 458,693 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 11,975 | $16.93 | $202,736.75 |
DisclosureSEC source: 0001209191-20-059242 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,043 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.71 to $17.46. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 22:38 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 11,885 | $19.67 | $233,777.95 |
DisclosureSEC source: 0001209191-20-047615 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,018 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.35 to $19.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| May 18, 2020 Filed May 20, 2020 22:30 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 8,968 | $22.51 | $201,869.68 |
DisclosureSEC source: 0001209191-20-031015 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,903 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.29 to $22.76. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 23:38 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 8,448 | $22.35 | $188,812.80 |
DisclosureSEC source: 0001209191-20-011261 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,871 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.00 to $23.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 02:35 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 44,600 | $0.00 Strike: $21.79 | $0.00 |
DisclosureSEC source: 0001209191-19-060788 · doc4.xml · derivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,600 Underlying: Common Stock · 44,600 shares Expires 2027-12-11 F2 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 02:35 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 167,650 | $0.00 Strike: $21.79 | $0.00 |
DisclosureSEC source: 0001209191-19-060788 · doc4.xml · derivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,650 Underlying: Common Stock · 167,650 shares Expires 2027-12-11 F2 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 02:35 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 94,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-060788 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,319 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service. Read SEC document |
| November 18, 2019 Filed Nov 21, 2019 00:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 13,556 | $17.97 | $243,601.32 |
DisclosureSEC source: 0001209191-19-057490 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,219 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.56 to $19.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| October 17, 2019 Filed Oct 17, 2019 23:00 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 33,333 | $0.00 Strike: $7.21 | $0.00 |
DisclosureSEC source: 0001209191-19-053498 · doc4.xml · derivative · entry 11 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,333 shares Expires 2020-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| October 17, 2019 Filed Oct 17, 2019 23:00 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 33,333 | $17.68 | $589,327.44 |
DisclosureSEC source: 0001209191-19-053498 · doc4.xml · nonDerivative · entry 7 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,775 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $17.44 to $17.88. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| October 17, 2019 Filed Oct 17, 2019 23:00 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 33,333 | $7.21 | $240,330.93 |
DisclosureSEC source: 0001209191-19-053498 · doc4.xml · nonDerivative · entry 6 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| October 16, 2019 Filed Oct 17, 2019 23:00 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 33,334 | $0.00 Strike: $7.21 | $0.00 |
DisclosureSEC source: 0001209191-19-053498 · doc4.xml · derivative · entry 10 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,333 Underlying: Common Stock · 33,334 shares Expires 2020-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| October 16, 2019 Filed Oct 17, 2019 23:00 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 33,334 | $17.48 | $582,678.32 |
DisclosureSEC source: 0001209191-19-053498 · doc4.xml · nonDerivative · entry 5 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,775 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $17.15 to $17.69. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| October 16, 2019 Filed Oct 17, 2019 23:00 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 33,334 | $7.21 | $240,338.14 |
DisclosureSEC source: 0001209191-19-053498 · doc4.xml · nonDerivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 23:00 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 33,333 | $0.00 Strike: $7.21 | $0.00 |
DisclosureSEC source: 0001209191-19-053498 · doc4.xml · derivative · entry 9 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,667 Underlying: Common Stock · 33,333 shares Expires 2020-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 23:00 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 24,500 | $17.17 | $420,665.00 |
DisclosureSEC source: 0001209191-19-053498 · doc4.xml · nonDerivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,775 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $16.88 to $17.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 23:00 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 8,833 | $16.35 | $144,419.55 |
DisclosureSEC source: 0001209191-19-053498 · doc4.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,275 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.81 to $16.77. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 23:00 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 33,333 | $7.21 | $240,330.93 |
DisclosureSEC source: 0001209191-19-053498 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| August 23, 2019 Filed Aug 26, 2019 21:21 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock · Derivative | 30,000 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001209191-19-047423 · doc4.xml · derivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 30,000 shares Expires 2022-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2019 Filed Aug 26, 2019 21:21 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 30,000 | $16.31 | $489,300.00 |
DisclosureSEC source: 0001209191-19-047423 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 23:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 12,551 | $18.15 | $227,800.65 |
DisclosureSEC source: 0001209191-19-046720 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,775 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.87 to $18.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| July 25, 2019 Filed Jul 26, 2019 00:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock · Derivative | 33,333 | $0.00 Strike: $7.21 | $0.00 |
DisclosureSEC source: 0001209191-19-043289 · doc4.xml · derivative · entry 10 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 33,333 shares Expires 2020-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| July 25, 2019 Filed Jul 26, 2019 00:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 33,333 | $29.65 | $988,323.45 |
DisclosureSEC source: 0001209191-19-043289 · doc4.xml · nonDerivative · entry 6 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,326 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $28.67 to $31.76. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| July 25, 2019 Filed Jul 26, 2019 00:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 33,333 | $7.21 | $240,330.93 |
DisclosureSEC source: 0001209191-19-043289 · doc4.xml · nonDerivative · entry 5 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 00:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock · Derivative | 33,334 | $0.00 Strike: $7.21 | $0.00 |
DisclosureSEC source: 0001209191-19-043289 · doc4.xml · derivative · entry 9 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,333 Underlying: Common Stock · 33,334 shares Expires 2020-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 00:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 33,334 | $32.11 | $1,070,354.74 |
DisclosureSEC source: 0001209191-19-043289 · doc4.xml · nonDerivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,326 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $31.90 to $32.22. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.